Liraglutide (Saxenda) Shows Promise for Weight Loss in Children Aged 6-11
• A Phase III trial of liraglutide (Saxenda) demonstrated a significant reduction in BMI in children aged 6-11 with obesity, compared to placebo.
• The study, presented at EASD 2024, showed a 5.8% mean reduction in BMI in the liraglutide group versus a 1.6% increase in the placebo group.
• Novo Nordisk plans to seek regulatory approval to expand the label for Saxenda to include children older than 6 years, potentially offering a new treatment option for this age group.
• While generally safe, liraglutide was associated with gastrointestinal side effects, and BMI tended to increase again after stopping the medication.
© Copyright 2025. All Rights Reserved by MedPath